These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 10950845)
1. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Mayhew BS; Jones DR; Hall SD Drug Metab Dispos; 2000 Sep; 28(9):1031-7. PubMed ID: 10950845 [TBL] [Abstract][Full Text] [Related]
2. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Sutton D; Butler AM; Nadin L; Murray M J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567 [TBL] [Abstract][Full Text] [Related]
3. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Ball SE; Ahern D; Scatina J; Kao J Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822 [TBL] [Abstract][Full Text] [Related]
4. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. Liu ZQ; Zhu B; Tan YF; Tan ZR; Wang LS; Huang SL; Shu Y; Zhou HH J Pharmacol Exp Ther; 2002 Jan; 300(1):105-11. PubMed ID: 11752104 [TBL] [Abstract][Full Text] [Related]
5. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603 [TBL] [Abstract][Full Text] [Related]
6. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485 [TBL] [Abstract][Full Text] [Related]
7. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. von Moltke LL; Greenblatt DJ; Schmider J; Duan SX; Wright CE; Harmatz JS; Shader RI J Clin Pharmacol; 1996 Sep; 36(9):783-91. PubMed ID: 8889898 [TBL] [Abstract][Full Text] [Related]
8. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214 [TBL] [Abstract][Full Text] [Related]
9. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658 [TBL] [Abstract][Full Text] [Related]
10. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro. Ring BJ; Binkley SN; Roskos L; Wrighton SA J Pharmacol Exp Ther; 1995 Dec; 275(3):1131-5. PubMed ID: 8531073 [TBL] [Abstract][Full Text] [Related]
11. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. Butler AM; Murray M J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313 [TBL] [Abstract][Full Text] [Related]
12. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717 [TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571 [TBL] [Abstract][Full Text] [Related]
14. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. Venkatakrishnan K; von Moltke LL; Greenblatt DJ J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960 [TBL] [Abstract][Full Text] [Related]
15. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Ohno Y; Hisaka A; Suzuki H Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375 [TBL] [Abstract][Full Text] [Related]
16. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Galetin A; Burt H; Gibbons L; Houston JB Drug Metab Dispos; 2006 Jan; 34(1):166-75. PubMed ID: 16221752 [TBL] [Abstract][Full Text] [Related]
17. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640 [TBL] [Abstract][Full Text] [Related]
18. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Ereshefsky L; Riesenman C; Lam YW Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618 [TBL] [Abstract][Full Text] [Related]
19. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Ghosal A; Satoh H; Thomas PE; Bush E; Moore D Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602 [TBL] [Abstract][Full Text] [Related]
20. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Hyland R; Roe EG; Jones BC; Smith DA Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]